Manufacturing Business Valuation Multiples (2026): Sub-Vertical Ranges, Sources, and What Drives Them

The phrase ‘manufacturing business valuation multiples’ describes a spectrum, not a number. Headline industry medians published quarterly by GF Data DealStats, BVR DealStats, and Pitchbook industrials reports (typically reporting LMM transactions in the 6-9x TEV/EBITDA range) describe a population dominated by $10-50M EBITDA businesses with strong recurring revenue and clean concentration profiles. Individual deals range from 3x SDE for sub-$1M owner-operated machine shops to 12x+ EBITDA for FDA-registered medical device CMs with 5-year regulatory lock-in. The 9-turn variance is real, and getting your sub-vertical and size band right is the entire game. For a deeper look, see our guide on landscaping business valuation.

This guide documents the actual multiple ranges by manufacturing sub-vertical in 2026, the data sources buyers use to triangulate them, and the structural drivers that explain why the bands diverge. We’ll cover the general framework (TEV/EBITDA versus SDE, size bands, capital intensity normalization), sub-vertical-specific ranges (machine shops, contract manufacturers, precision machining, aerospace, medical device, plastics, electronics CMs, metal stamping, fabrication), the four primary multiple drivers (capital intensity, customer concentration, recurring revenue percentage, recession sensitivity), and the data sources that ground these ranges (GF Data, BVR DealStats, Pitchbook, MAPI, AMT, NTMA, public 10-K disclosures from serial acquirers). For a deeper look, see our guide on roofing company valuation.

The framework draws on direct work with 76+ active U.S. lower middle-market buyers — including 38 firms (50% of the network) with explicit manufacturing mandates. These buyers include manufacturing-focused PE platforms (Audax Industrial Services, Industrial Growth Partners, GenNx360 Capital Partners, Trive Capital, Mason Wells, Wynnchurch Capital, Argosy Capital, Sterling Group, Cortec Group, GTCR’s industrials practice, Genstar Capital industrial investments, Carlyle Industrials, Bain Capital Industrials, Onex industrial investments), public strategic consolidators (NYSE: APi Group [APG], NYSE: Watsco [WSO], NYSE: Comfort Systems USA [FIX], NYSE: Roper Technologies [ROP], NASDAQ: HEICO [HEI], NYSE: Atkore [ATKR], TransDigm), family offices with industrial mandates, and the broader sub-LMM ecosystem of search funders, independent sponsors, and SBA buyers. We’re a buy-side partner. The buyers pay us when a deal closes — not you.

One realistic note before you start. The multiple ranges in this guide are starting points, not commitments. Real valuations live in a 25-35% range around any published multiple, and the actual price your business achieves depends on which buyers see it (sub-vertical match), what your books look like under QoE (financial cleanup), and how the deal structure resolves (asset versus stock, working capital peg, seller financing, earnout). Use these multiples to triangulate a defensible range — then validate against actual buyer feedback before treating any number as final.

“There is no single ‘manufacturing multiple’ in 2026. There is a spectrum from 3x SDE for a sub-$1M owner-operated job shop to 12x EBITDA for a $25M EBITDA medical device CM with FDA registration and 75% recurring contracted revenue. The 4-turn gap between ‘manufacturing’ and ‘medical device CM with the right certifications’ is real, defensible, and grounded in capital structure mathematics — not aspirational pricing. Knowing which point on the spectrum you actually occupy is the entire valuation question.” For a deeper look, see our guide on unlock industry specific valuation multiples for ma success.

Key Takeaways

• TEV/EBITDA framework by size: sub-$10M = 4-7x, $10-50M = 6-9x, $50M+ = 7-12x (GF Data, BVR DealStats, Pitchbook industrials, 2024-2026).
• Sub-vertical ranges in 2026: machine shop 3-5x SDE, contract manufacturer 5-7x EBITDA, precision machining 6-8x EBITDA, aerospace AS9100/NADCAP 7-10x EBITDA, medical device ISO 13485/FDA 8-12x EBITDA.
• Four primary drivers of multiple variance: capital intensity (4-7% maintenance capex typical), customer concentration (25%/40%/50% thresholds), recurring contracted revenue percentage (60%+ supports premium), and recession sensitivity by end-market.
• Data triangulation: combine GF Data DealStats, BVR DealStats, Pitchbook industrials, public 10-K disclosures from NASDAQ: HEICO and NYSE: Atkore, plus trade association data from MAPI, AMT, NTMA, PMA.
• Recession sensitivity by sub-vertical: aerospace and medical device CMs most resilient, automotive Tier-2 and construction equipment CMs most cyclical, swing of 1-2 turns at cycle troughs.
• Strategic synergy premiums: public consolidators (APi Group, Watsco, Comfort Systems, Roper, HEICO, Atkore) often pay 1-2 turns above LMM PE multiples for the right strategic fit.

The 2026 manufacturing multiple framework: how sophisticated buyers actually price

Manufacturing valuation in 2026 follows a layered framework: base multiple by sub-vertical and size band, then four structural adjusters (capital intensity, customer concentration, recurring revenue percentage, growth profile), then deal-specific factors (asset versus stock structure, working capital peg, seller financing, earnout exposure). Each layer explains a turn or two of the final multiple. Skip any layer and your valuation is materially off. Sophisticated LMM PE buyers (Audax Industrial, Industrial Growth Partners, GenNx360, Trive Capital, Mason Wells, Wynnchurch, Sterling Group, Argosy Capital, Cortec Group) and public strategic consolidators run all of these adjusters during diligence regardless of how the seller priced the deal. Knowing the framework protects the seller; ignoring it cedes the analysis to the buyer.

Headline TEV/EBITDA multiples by size band (2026 vintage): Sub-$2M EBITDA: 3-5x SDE for owner-operated machine shops; 4-6x EBITDA for businesses with real second-tier management. $2-5M EBITDA: 5-7x EBITDA, the entry to LMM PE competition. $5-10M EBITDA: 6-7.5x EBITDA, full LMM PE buyer pool. $10-25M EBITDA: 6.5-8.5x EBITDA, the heart of LMM with active competition. $25-50M EBITDA: 7-9.5x EBITDA, upper LMM and lower middle market meet. $50M+ EBITDA: 8-12x EBITDA, true middle market with strategic premium available. These are the central tendencies; sub-vertical adjusters move you 1-3 turns inside or outside these bands.

Why size matters in non-linear ways. LMM PE platforms typically have minimum check sizes of $5-10M of equity capital deployed per platform. Backing into the EBITDA threshold that supports those checks at typical LMM multiples (5-7x) and capital structures (40-60% leverage) produces a $2-3M EBITDA floor. Below that floor, the buyer pool collapses to search funders, independent sponsors, SBA-financed individuals, and PE add-on programs — each with capital structures that mathematically force lower multiples. The structural break at $2-3M EBITDA is real and explains why the same business at $1.8M EBITDA versus $3.2M EBITDA trades at materially different multiples.

TEV versus equity value mechanics. TEV (total enterprise value) is the price a buyer pays for the operating business: equity value plus assumed debt, minus excess cash, with a working capital target. TEV is what the buyer underwrites and what trade press reports. Equity proceeds are what the seller actually receives: TEV − debt at close + excess cash ± working capital adjustment − transaction costs. On a $20M TEV deal with $1.5M debt, $400K excess cash, neutral working capital, and 1.5% transaction costs, equity proceeds before tax are roughly $18.6M. The multiple is on TEV; the wire is on equity. Both numbers matter.

Sub-vertical multiples in 2026: machine shops to medical device CMs

Manufacturing sub-verticals trade in distinct multiple bands driven by certification requirements, recurring revenue depth, capital intensity, and end-market growth profile. The 4-turn spread between a $5M EBITDA general contract manufacturer (typically 5.5-6.5x) and a $5M EBITDA AS9100-certified aerospace precision shop (typically 7.5-9x) is grounded in real economic differences: certification scarcity, OEM qualification cycles of 18-36 months, and 60-80% recurring contracted revenue under multi-year LTAs.

General machine shops (no specialty certifications): 3-5x SDE for sub-$1M SDE, 4-6x EBITDA for $1-3M EBITDA. Hallmarks: 5-25 employees, $2-12M revenue, 8-15% EBITDA margins, broad customer mix without certification gating, owner often still doing customer-facing work or shop-floor labor. Buyers: SBA-financed individuals dominate sub-$1M SDE; search funders and independent sponsors active in $1-3M EBITDA. Multiple compression below 3x SDE happens when the owner is the lead programmer or estimator and the business cannot survive a 30-day owner absence. ISO 9001 alone does not move the multiple meaningfully — it’s baseline.

Contract manufacturers (general industrial CM): 5-7x EBITDA for $2-10M EBITDA, 6-8x for $10-25M EBITDA. Hallmarks: defined production processes for established OEM customers, multi-year supply agreements common, 60-80% recurring contracted revenue, ISO 9001 baseline. Active LMM buyers: Trive Capital (multiple plastics platforms), Mason Wells (industrial CM), Wynnchurch Capital (metal fabrication), Argosy Capital (specialty CM). Strategic consolidators in industrial CM include NYSE: Atkore (ATKR) for electrical product CMs and Roper Technologies (ROP) subsidiaries for niche industrial equipment. Capex intensity varies widely within this sub-vertical: light-asset CMs (assembly, finishing) trade higher; heavy-asset CMs (injection molding, stamping) trade 0.5-1 turn lower due to capex burden.

Precision machining (tight-tolerance, ISO 9001 minimum): 6-8x EBITDA for $3-15M EBITDA, 7-9x for $15M+ EBITDA. Hallmarks: dimensional tolerances of 0.001” or better, end-markets including medical instruments (non-implantable), industrial pumps, hydraulics, fluid power, automotive Tier-2. ISO 9001 is table stakes; ISO 13485 (medical) or AS9100 (aerospace) opens premium buyer pools. Active buyers: GenNx360 Capital Partners, Sterling Group, Industrial Growth Partners, plus strategic consolidators in fluid power (Roper Technologies subsidiaries, Helios Technologies, Parker Hannifin acquisition arm). Higher gross margins (32-42% typical) and lower capital intensity than commodity CMs support the premium versus general CMs.

Aerospace contract manufacturers and precision shops (AS9100 / NADCAP): 7-10x EBITDA for $3-25M EBITDA, 8-12x for $25M+ EBITDA. Hallmarks: AS9100D quality system, NADCAP accreditation for special processes (NDT, heat treat, chemical processing, welding, magnetic particle inspection), Tier-1 OEM qualification (Boeing, Airbus, Lockheed Martin, Northrop Grumman, Raytheon, Spirit AeroSystems, Textron, Bombardier), 60-80% recurring contracted revenue under 3-5 year LTAs. Active aerospace LMM buyers: GenNx360 Capital Partners, Audax Industrial Services, GTCR Industrials, Arlington Capital Partners, Greenbriar Equity Group, Cortec Group, Liberty Hall Capital Partners. Strategic consolidators: NASDAQ: HEICO (HEI) for specialty aerospace components and aftermarket parts (HEICO has acquired 100+ companies and built a $20B+ market cap on aerospace aftermarket consolidation), TransDigm for proprietary aerospace components, NYSE: Roper Technologies (ROP) subsidiaries for niche aerospace equipment. ITAR-restricted defense work adds 0.5-1 turn premium for U.S.-controlled buyers.

Medical device contract manufacturers (ISO 13485 / FDA registered): 8-12x EBITDA for $3-30M EBITDA, with strategic outliers above 12x. Hallmarks: FDA 21 CFR Part 820 quality system, ISO 13485 certification, 2-5 year regulatory submission and qualification cycles, 70%+ recurring contracted revenue, demographic-aging tailwind. Buyers: medical-focused PE (Linden Capital Partners, Riverside Healthcare Capital Group, GTCR Healthcare, Bain Capital Healthcare, NewSpring Capital Healthcare practice, Avista Capital, Frazier Healthcare Partners), strategic acquirers consolidating medical CM (Integer Holdings [NYSE: ITGR], Heraeus Medical Components, Phillips-Medisize, Tecomet, Cretex Medical). Capex intensity is higher (6-10% of revenue) but multiple expansion compensates. Class III implantable device CMs trade at the very top of the range (10-13x) due to regulatory moat depth.

Plastics injection molding and metal stamping/fabrication: 4.5-6.5x EBITDA for $2-10M EBITDA, 5.5-7.5x for $10M+ EBITDA. Hallmarks: high capex intensity (6-9% of revenue for injection molding, 5-8% for stamping), recurring contracted production parts on OEM bills of materials, customer concentration often higher than other CM sub-verticals (Tier-2 automotive, industrial equipment OEMs). Active buyers: Trive Capital (multiple plastics platforms), Wynnchurch Capital (metal fabrication), Mason Wells (industrial CM), Argosy Capital. Capex intensity is the primary multiple-compressor versus precision and CM averages. Owners who can document a clean 5-year capex history and equipment replacement plan protect the multiple; owners with deferred capex see 1-2 turns of compression at QoE.

Electronic contract manufacturers (ECM / EMS): 5-7x EBITDA for $3-15M EBITDA, 6-8x for $15M+ EBITDA. Hallmarks: light capex (3-5% of revenue) but heavy inventory and component-cost pass-through, gross margins compressed (12-22%) by component cost dynamics, customer concentration often high. Sub-categories include PCB assembly, full box-build EMS, IPC Class 3 (high-reliability) EMS, and medical/aerospace-qualified EMS. Active buyers in ECM/EMS: TPG Capital industrial investments, Genstar Capital, Trive Capital, Bain Capital industrials. Strategic consolidators include Sanmina, Jabil, Benchmark Electronics, Plexus.

Driver 1: capital intensity and the gap between reported and cash EBITDA

Capital intensity is the single most-misunderstood driver of manufacturing valuation. Reported EBITDA — which adds back depreciation — ignores the equipment replacement obligation that defines manufacturing. A CNC machine shop, a plastic injection molder, a metal stamping operation runs on equipment that depreciates in 5-15 years and requires ongoing replacement to maintain capacity. Sophisticated buyers underwrite to cash EBITDA = reported EBITDA − 3-year average maintenance capex. The gap is typically 15-30% of reported EBITDA — meaningful enough to shift multiple decisions by 1-2 turns.

Maintenance capex benchmarks by sub-vertical (2024-2026 industry data, AMT and trade association sources): General machine shops: 3-5% of revenue. Precision machining: 5-7% of revenue. Plastic injection molding: 6-9% of revenue (heavy press and tooling investment, mold maintenance). Metal stamping and forming: 5-8% of revenue. Aerospace machining (AS9100): 5-8% of revenue plus 2-4% in tooling-specific spend (qualification fixtures, gauges). Medical device CMs: 6-10% of revenue with cleanroom infrastructure, validated equipment, and lot traceability systems. Electronic contract manufacturing: 3-5% of revenue (lighter capex, but inventory-heavy).

How buyers actually run the math during diligence. QoE providers (Plante Moran, BDO, Crowe, RSM Manufacturing & Distribution practice, Wipfli, Eide Bailly, Cohn Reznick) request 5-year capex history with line-item detail: equipment purchases, mold investments, IT/ERP capex, building improvements, qualification capex (validation lots, customer-specific tooling). They categorize each spend as maintenance versus growth. They benchmark the maintenance percentage against sub-vertical norms. They ask the seller’s CFO or controller for the next 5 years of forward capex projection tied to specific equipment age and replacement schedule. Owners who walk in with this data already organized protect the multiple; owners who don’t cede the analysis to buyer assumption.

Equipment age and the ‘deferred capex’ trap. If your reported EBITDA is artificially elevated because you’ve deferred 3-5 years of equipment refresh capex, sophisticated QoE will catch it. The fix isn’t to keep deferring; it’s to acknowledge the capex liability up front and price the deal accordingly. A precision shop with 15-year-old CNC equipment may need $2-4M of replacement capex in the next 3-5 years to maintain capacity; that future obligation reduces the realistic multiple by 0.5-1 turn versus a comparable shop with a clean 5-year capex history.

Capex intensity by recession scenario. In recessionary periods, owners often defer capex to preserve cash flow. This temporarily inflates reported EBITDA but creates a future liability that buyers detect. Cycle-aware QoE providers will normalize maintenance capex to a multi-cycle average (often using a 5-7 year window) rather than the trailing 3 years. Owners going to market in late-cycle conditions (or after a recession) need to be especially careful about capex normalization in their diligence package.

Driver 2: customer concentration thresholds and how disciplined buyers price them

Customer concentration is the single biggest qualitative risk factor in manufacturing M&A and one of the most systematically priced. The thresholds are well-known to any disciplined LMM buyer: under 15% concentration is treated as broadly diversified and earns no discount. 15-25% concentration is acknowledged but rarely repriced. 25-40% concentration triggers a 0.5-1.5 turn multiple discount and conversations about earnouts or escrow. 40-50% concentration pushes most LMM PE platforms to require an earnout structure tied to customer retention. Above 50% concentration, the deal compresses 1.5-3 turns and structure becomes heavily contingent.

Why concentration matters more in manufacturing than in service businesses. Manufacturing customer relationships are typically embedded in OEM supply chains with long qualification cycles (12-36 months for aerospace, 6-18 months for medical device, 3-12 months for industrial). The lock-in is real but the fall is also catastrophic. Losing a 35% Boeing program to a competitor through a re-quote isn’t recoverable in 6 months; it’s recoverable in 2-4 years if at all. Buyers know this. Audax Industrial, Industrial Growth Partners, Sterling Group, Wynnchurch, GenNx360, Trive Capital all model the ‘what if’ scenario of losing the top customer and discount the multiple to compensate.

Mitigations that protect the multiple. Long-term agreements (3-5 year LTAs with stated volume commitments and pricing escalators tied to PPI or CPI manufacturing indices). Sole-source designations on critical part numbers (sticky but riskier if OEM dual-sources). Embedded engineering relationships (your application engineer is in the OEM’s product development meetings). Capacity reservation agreements where the OEM has paid for dedicated production capacity. Multi-program presence at a single OEM (you’re on 12 programs across three Boeing business units, not just one). AS9100 / ISO 13485 / NADCAP certifications that make switching costly. Each of these meaningfully reduces the practical concentration risk and the discount the buyer applies.

How sophisticated buyers stress-test concentration. They request 36-60 months of customer-by-customer revenue history. They ask whether each top relationship is a long-term agreement (LTA) or a series of purchase orders. They ask about pricing reset mechanisms (annual, biennial, indexed to commodity prices). They ask whether the customer relationship runs through one or two engineers at the OEM (key-person risk on the customer side). They ask whether you have qualified second-source suppliers or whether you are sole-sourced. They ask about recent re-quotes or RFQs you’ve participated in. Owners who walk into diligence without this analysis ready cede the conversation.

Driver 3: recurring contracted revenue percentage and the LTA premium

Recurring contracted revenue is the single biggest multiple-expander in manufacturing. Buyers pay materially more for businesses where 60%+ of revenue is under multi-year contracted supply agreements with built-in volume commitments and pricing escalators than they do for businesses with the same EBITDA derived from project-based work or transactional purchase orders. The reasoning is straightforward: contracted revenue is forecastable, recession-resistant within OEM cycles, and supports higher leverage in the buyer’s capital structure (which translates directly to higher multiples).

What counts as recurring in manufacturing. Multi-year supply agreements (LTAs) with stated volume commitments and pricing escalators. Production parts on an OEM bill of materials with sole-source or qualified-second-source designation. Aftermarket service parts where the OEM has installed-base equipment that will continue to need replacement parts for 10-20+ years (NASDAQ: HEICO [HEI] built a $20B+ market cap on aerospace aftermarket; the same dynamic exists in industrial pumps, valves, hydraulics, and fluid power). Repeat-order industrial commodity production (gaskets, fasteners, bearings, hydraulic components, electrical connectors) where customer churn is structurally low.

What does NOT count as recurring. ‘Repeat customers’ without contracted volume commitments are not recurring — they are loyal. Repeat customers can disappear in a single quarter if a competitor under-quotes a re-bid. Project-based work for the same customer (custom tooling, one-off fabrications, prototype runs) is not recurring even if the customer comes back annually. MRO (maintenance/repair/overhaul) work is borderline — if it’s under a multi-year service contract with volume commitments, it counts; if it’s ad-hoc, it doesn’t.

Multiple impact by recurring revenue percentage. 30% recurring or below: discount of 0.5-1 turn versus the sub-vertical median. 30-50% recurring: at-median pricing. 50-70% recurring: premium of 0.5 turn. 70%+ recurring: premium of 1-1.5 turns and access to the premium buyer pool (LMM PE platforms specifically focused on industrial repeat-revenue businesses, plus strategic consolidators). The recurring-revenue premium is more durable than most other adjusters — it survives sub-vertical cycles, customer concentration concerns, and even capital intensity issues.

Driver 4: recession sensitivity and end-market exposure

Manufacturing sub-verticals have very different recession sensitivity profiles. Aerospace (commercial and defense) and medical device CMs are the most recession-resilient: aerospace because OEM production rates are set 3-5 years in advance and qualification cycles lock in incumbents through cycle troughs, defense because government procurement is counter-cyclical, and medical because demographic demand is recession-independent. Automotive Tier-2 (especially passenger vehicle exposure), construction equipment CMs, and industrial CMs serving cyclical end-markets (oil and gas, mining, agriculture) compress 1-2 turns at cycle troughs.

Recession sensitivity by sub-vertical: Aerospace commercial: low sensitivity, but with 18-36 month lag (production rates set in advance). Aerospace defense: counter-cyclical (government spending tends to support during recessions). Medical device (Class II/III implantable, surgical, diagnostic): minimal sensitivity. General industrial CMs serving diversified end-markets: moderate sensitivity, 0.5-1 turn compression at cycle troughs. Automotive Tier-2 (passenger vehicle): high sensitivity, 1-2 turn compression at cycle troughs. Construction equipment CMs: high sensitivity, 1-2 turn compression. Oil and gas equipment CMs: very high sensitivity, 1.5-3 turn compression and binary in extreme cycles. Agriculture equipment CMs: high sensitivity tied to commodity prices.

How sophisticated buyers price recession sensitivity. They run cycle-adjusted EBITDA scenarios using historical financials through 2008-2010, 2014-2016 (oil and gas trough), 2019-2020 (COVID), and 2023 if relevant. They build forward-looking projections under a base case, downside case, and stress case. They apply the multiple to mid-cycle EBITDA, not peak EBITDA. Owners going to market in late-cycle conditions need to be especially careful about pricing on TTM EBITDA — if TTM is peak-cycle, sophisticated buyers will normalize down.

End-market diversification as recession protection. A precision machining business with 60% aerospace and 40% medical device end-market exposure trades materially better than the same business with 100% automotive Tier-2 exposure — even at the same EBITDA. Diversified end-market exposure protects multiples through cycles and commands premium pricing. The shift toward end-market diversification is one of the biggest 12-24 month preparation moves an owner can make: actively pursuing customer wins outside the dominant end-market reduces practical recession sensitivity and supports a 0.5-1 turn premium.

Data sources: where the multiples in this guide actually come from

The multiple ranges in this guide are triangulated from five primary data sources used by sophisticated LMM PE buyers and M&A advisors in 2026. (1) GF Data DealStats: quarterly multiple data on completed LMM transactions, segmented by industry NAICS code and size band. Best for LMM (sub-$50M TEV) deal multiples. (2) BVR DealStats: comprehensive M&A multiples database with sub-vertical breakdowns. Strong on private-market transactions across size ranges. (3) Pitchbook industrials reports: aggregated PE deal flow and multiples across LMM and middle market. Best for trend analysis and aggregate market context. (4) Public 10-K disclosures from serial acquirers in industrials: NASDAQ: HEICO (HEI), NYSE: Atkore (ATKR), NYSE: Roper Technologies (ROP), TransDigm Group, NYSE: APi Group (APG). Best for precise individual deal metrics in the strategic-premium band. (5) Trade association data: Manufacturers Alliance (MAPI) economic surveys, Association for Manufacturing Technology (AMT) economic reports, National Tooling and Machining Association (NTMA) member surveys, Precision Metalforming Association (PMA) industry data, National Association of Manufacturers (NAM) policy and economic data.

Government and macroeconomic data for context. U.S. Bureau of Labor Statistics (BLS) manufacturing employment, wage, and productivity data. U.S. Bureau of Economic Analysis (BEA) GDP-by-industry data tracking manufacturing sector performance. Federal Reserve industrial production index tracking utilization and capacity. U.S. Census Bureau Annual Survey of Manufactures (ASM) and Quarterly Financial Report providing detailed sub-vertical financial data. None of these directly inform multiples, but they provide the macroeconomic context buyers use to underwrite forward-looking projections and recession sensitivity.

Sub-vertical-specific industry research. IBISWorld manufacturing industry reports (often available through public library systems) provide sub-vertical market sizing, growth trends, competitive intensity analysis, and supply-chain dynamics. First Research industry reports (a Mergent product) provide similar sub-vertical analysis. Frost & Sullivan analysts publish detailed reports on aerospace CM, medical device CM, and other premium sub-verticals. These are useful for buyers building investment theses but not directly for setting multiples; they inform the ‘why pay this multiple’ story rather than the multiple itself.

How to triangulate as a seller. Start with the sub-vertical multiple range from this guide (which is itself triangulated from the sources above). Apply the size adjuster from GF Data. Apply concentration and recurring revenue adjusters from your specific profile. Cross-reference recent strategic deals from public 10-Ks (for synergy-premium upside cases). Validate operational benchmarks against trade association data (gross margin, revenue per employee, on-time delivery, first-pass yield). The triangulated estimate is a defensible range, not a single number. Use it as input to validation conversations with actual buyer-network professionals, not as a final answer.

Public consolidator strategic premiums: when synergy buyers pay above LMM PE

Public strategic consolidators in industrials often pay 1-2 turns above the LMM PE multiple band when the strategic fit is clear. The mechanics are straightforward: a public consolidator’s cost of capital is lower than a PE platform’s (public equity markets versus 7-9% PE-fund hurdle plus debt cost), and synergy economics (revenue cross-sell, cost takeout, geographic coverage, capability expansion) create real after-acquisition EBITDA uplift that the buyer is willing to pay for at signing. Recent disclosed deals from NASDAQ: HEICO (HEI), NYSE: APi Group (APG), NYSE: Atkore (ATKR), NYSE: Roper Technologies (ROP), TransDigm, NYSE: Watsco (WSO), NYSE: Comfort Systems USA (FIX) provide the public benchmarks.

NASDAQ: HEICO (HEI) — aerospace aftermarket consolidator. HEICO has built a $20B+ market cap by acquiring 100+ specialty aerospace component businesses since 1990. Recent deals disclosed in HEICO 10-K filings have ranged from 7-12x EBITDA depending on certification depth, customer relationships, and aftermarket parts library. HEICO’s edge: long-cycle aftermarket revenue from installed-base aerospace fleets, FAA Parts Manufacturer Approval (PMA) library that compounds in value, and 20+ years of operational integration playbook.

NYSE: APi Group (APG) — specialty contractor consolidator. APi Group has built a $14B+ market cap by consolidating specialty contractor businesses, including a meaningful manufacturing component for fire protection equipment, specialty metals fabrication, and HVAC components. Public disclosures have indicated acquisition multiples in the 7-10x EBITDA range for the specialty manufacturing tuck-ins, with strategic premium driven by route density, technician overlap, and customer cross-sell.

NYSE: Roper Technologies (ROP) — niche industrial software and equipment. Roper has built a $50B+ market cap through 100+ acquisitions of niche industrial software, measurement, and analytical equipment businesses. Roper’s acquisition multiples disclosed in 10-K filings have averaged 12-16x EBITDA, the highest in the industrials consolidator space — reflecting the niche-monopoly thesis (products with no real substitutes), 80%+ recurring revenue characteristics in the target software businesses, and Roper’s decentralized operating model. Roper-style deals are at the very top of the industrials multiple range, accessible only to businesses with truly differentiated positions.

TransDigm Group — proprietary aerospace components. TransDigm has built a $90B+ market cap by acquiring proprietary, sole-source aerospace component manufacturers. Public disclosures and trade press have indicated acquisition multiples in the 10-15x EBITDA range, reflecting 70%+ recurring aftermarket revenue, FAA-certified proprietary positions, and pricing power from sole-source designations. TransDigm-quality businesses are rare but command the highest multiples in aerospace M&A.

NYSE: Atkore (ATKR) and NYSE: Watsco (WSO) — electrical and HVAC distribution and adjacent CM. Atkore (electrical raceway and conduit) and Watsco (HVAC distribution with adjacent equipment manufacturing) consolidate manufacturing and distribution platforms in their respective sectors. Acquisition multiples disclosed have been in the 7-10x EBITDA range, with premium driven by route density and customer-base cross-sell. NYSE: Comfort Systems USA (FIX) has acquired mechanical contractors with embedded manufacturing capability at similar multiples.

Where the LMM PE manufacturing buyer pool actually clusters

The 38 manufacturing-focused buyers in our 76+ buyer network cluster into four sub-archetypes based on size, sub-vertical focus, and operating model. Knowing which sub-archetype matches your business is the second-most-important positioning decision after sub-vertical identification. Mismatched outreach (running a process to mega-cap PE platforms for a $4M EBITDA business; running a process to search funders for a $25M EBITDA platform) wastes 6-12 months.

Sub-archetype 1: LMM PE manufacturing platform builders. Examples: Audax Industrial Services, Industrial Growth Partners (IGP), GenNx360 Capital Partners, Trive Capital, Mason Wells, Wynnchurch Capital, Argosy Capital, Sterling Group, Cortec Group, GTCR’s industrials practice. Check size: $5-50M+ of equity per platform. Multiples: 6-9x EBITDA for $5-25M EBITDA, 7-10x for $25-50M EBITDA. Hold period: 3-7 years. Value-creation thesis: operational improvement, add-on acquisitions, end-market diversification, geographic expansion. They want clean books, real second-tier management, recurring contracted revenue, and at least ISO 9001 quality systems.

Sub-archetype 2: Mega-cap PE industrial groups. Examples: KKR Industrials and (post-acquisition) Global Infrastructure Partners, Carlyle Industrials, Onex Partners industrial investments, Bain Capital industrials practice, Apollo Global Management industrials. Check size: $50-500M+ of equity per platform. Multiples: 8-12x for $25-100M EBITDA, 9-15x for $100M+ EBITDA. They typically buy platforms and use add-on programs to roll up sub-scale targets. They want $25M+ EBITDA, $100M+ revenue, defensible market positions, and growth runway.

Sub-archetype 3: Sector-specialist PE (medical device, aerospace, defense). Medical device CM specialists: Linden Capital Partners, Riverside Healthcare Capital Group, GTCR Healthcare, Bain Capital Healthcare, NewSpring Capital Healthcare practice, Avista Capital, Frazier Healthcare Partners. Aerospace and defense specialists: Arlington Capital Partners, Greenbriar Equity Group, GenNx360, Liberty Hall Capital Partners. Multiples: 8-12x EBITDA for medical CM; 7-10x for aerospace CM. These specialists pay premium to generalist LMM PE for sub-vertical fit because they understand the regulatory/qualification moat depth.

Sub-archetype 4: Family offices with industrial mandates. Names typically undisclosed by nature, but the 76+ buyer network includes 8-12 family offices with explicit manufacturing mandates and check sizes ranging from $5M to $100M of equity. Multiples: 5-8x EBITDA depending on situation. Family offices sometimes pay premium for strategic fit with existing portfolio companies but more often pay disciplined LMM-equivalent multiples with longer hold horizons (7-15 years versus 3-5 for PE). Process: less competitive on price but often faster on close because they don’t need fund-level approvals.

How sub-vertical multiples have shifted from 2019-2026

Manufacturing multiples have evolved meaningfully over the 2019-2026 cycle, with three distinct phases. Phase 1 (2019-2020 pre-COVID): multiples expanded for medical device and aerospace, compressed for automotive Tier-2 and oil-and-gas equipment CMs. Phase 2 (2020-2021 COVID and rebound): supply-chain reshoring narrative pushed all sub-verticals 0.5-1.5 turns higher; medical device CMs saw the strongest expansion (vaccine production capacity, surgical recovery demand). Phase 3 (2022-2024 rate-hike cycle): multiples compressed 0.5-1 turn across sub-verticals as rate increases pushed up cost of capital for PE buyers. Phase 4 (2025-2026): multiples have stabilized and partially recovered, with aerospace and medical device CMs back near 2021 peaks; automotive and construction equipment CMs remain compressed.

Aerospace specifically. Aerospace multiples were depressed in 2020-2021 (COVID-driven commercial production cuts) but rebounded sharply in 2022-2024 as Boeing 737 MAX recovery, Airbus A320 family rate increases, and military/defense spending all expanded. AS9100/NADCAP precision shop multiples in 2026 are typically 7-10x EBITDA versus 6-8x in 2020 — a meaningful 1-2 turn expansion. Tier-1 OEM rate increases support continued expansion through 2026-2028 if announced.

Medical device CM specifically. Medical device CM multiples have been the most resilient and consistently expanding sub-vertical. ISO 13485 / FDA-registered CMs trade at 8-12x EBITDA in 2026, up from 7-10x in 2019. Drivers: demographic-aging tailwind, regulatory moat depth, increasing OEM outsourcing trend, and active PE consolidation by specialists (Linden Capital Partners, Riverside Healthcare, GTCR Healthcare, Bain Capital Healthcare). Class III implantable device CMs trade at the very top of the range (10-13x) due to regulatory moat depth.

General CM and machine shop trajectories. General machine shop SDE multiples have been remarkably stable: 3-5x SDE in 2019, 3-5x SDE in 2026. The SBA-financed individual buyer pool dominates and is governed more by SBA loan economics than by macro multiple trends. General contract manufacturer EBITDA multiples have expanded modestly: 4.5-6x in 2019, 5-7x in 2026, driven by reshoring narrative and increased PE platform activity. Plastics injection molding multiples expanded materially from 2019 (3.5-5x) to 2024 (5-7x) on automotive recovery and aerospace pickup, then partially stabilized.

Working capital, debt, and the gap between TEV and equity proceeds

TEV multiples are headline numbers; equity proceeds are what the seller actually receives. The gap between TEV and equity proceeds in manufacturing M&A is typically 15-30%, driven by debt at close, working capital adjustment, transaction costs, and taxes. A $20M TEV deal often produces $13-16M of cash at close, with another $2-4M in seller financing collected over 7-10 years and $0-3M in earnout collected over 1-3 years.

Working capital math for manufacturing. Manufacturing businesses carry significant working capital: typically 20-30% of revenue depending on sub-vertical. The cash conversion cycle (DSO + inventory days − DPO) drives the peg. Aerospace precision shops with 50-day DSO, 90-day inventory days (long lead-time aerospace material), and 35-day DPO have a 105-day cycle — roughly 30% of revenue. On $14M revenue, that’s a $4.2M working capital target. Medical device CMs run similar profiles. General CMs run lighter (15-22% of revenue). Machine shops run lightest (12-18% of revenue).

The peg negotiation in the LOI. The working capital peg is typically calculated as a trailing 12-24 month average. Manufacturing businesses with seasonal patterns (HVAC component CMs, agricultural machinery CMs, pool and spa equipment CMs) need especially careful peg construction: a trailing average closing in a peak-inventory month systematically over-delivers working capital. A skilled M&A advisor or QoE provider negotiates a seasonally adjusted peg or a peak-trough corridor. Without that, the seller can give back $500K-$1.5M at close on a $20M deal — and most owners only realize this in the final week.

Excess cash and debt-free / cash-free mechanics. Cash sitting in the operating account at close is typically retained by the seller (the deal is ‘cash-free’). Debt is paid off at close from proceeds (the deal is ‘debt-free’). Equipment leases that are economically debt are usually treated as debt and reduce the equity check. Operating leases for facilities are not. The classification of equipment financing (capital lease, equipment finance loan, sale-leaseback) materially affects the equity proceeds and is one of the first things a sophisticated QoE provider scrubs.

How to use multiples in your sale planning (without anchoring on the wrong number)

Multiples are starting points for planning, not ending points for negotiation. The right way to use this guide is to triangulate a defensible range based on your sub-vertical, size band, and qualitative profile (concentration, recurring revenue, capex, certifications). The wrong way is to multiply your reported EBITDA by the high end of the published range and treat the result as a target. Multiples drive the conversation; the conversation drives the actual price.

Three planning decisions multiples should inform. (1) Should I sell now or wait 12-24 months? If your sub-vertical multiple band is structurally rising (aerospace, medical device CM) and your business is positioned to grow into a higher size band, waiting often pays. If the band is stable or declining (commodity CM, automotive Tier-2 in late cycle), selling sooner often pays. (2) Should I invest in certifications before selling? AS9100 certification adds 1-3 turns of multiple at the cost of 9-15 months and $50-150K of investment. ISO 13485 adds 2-4 turns of multiple at the cost of 12-18 months and $75-200K. The ROI is substantial for businesses with end-market exposure that supports the certification. (3) Should I pursue customer diversification before selling? Reducing top-customer concentration from 38% to 22% over 12-18 months typically adds 0.5-1.5 turns of multiple. The investment (sales effort, customer acquisition cost) is meaningful but the return is real.

Validation conversations that translate multiples into actual ranges. A 30-minute call with a buy-side partner who knows the manufacturing buyer pool is worth more than 5 hours of self-analysis. The conversation produces: realistic multiple range tied to your specific profile (not industry-wide median), identification of the 3-5 specific buyer archetypes who would actually look at your business, guidance on which 12-24 month preparation moves would change the multiple, and a structural read on which deal mechanics (asset versus stock, working capital peg, seller financing, earnout) typically apply for businesses like yours.

How CT Acquisitions runs this conversation. We work directly with 76+ active U.S. lower middle-market buyers, including 38 firms with explicit manufacturing mandates: Audax Industrial Services, Industrial Growth Partners, GenNx360 Capital Partners, Trive Capital, Mason Wells, Wynnchurch Capital, Argosy Capital, Sterling Group, Cortec Group, GTCR Industrials, Genstar Capital industrial investments, Carlyle Industrials, Bain Capital Industrials, Onex industrial investments, family offices with manufacturing mandates, public consolidators (NYSE: APi Group [APG], Watsco [WSO], Comfort Systems [FIX], Roper [ROP], NASDAQ: HEICO [HEI], NYSE: Atkore [ATKR]), and search funders/independent sponsors. Buyers pay us when a deal closes. You pay nothing — no retainer, no contract.

Conclusion

Manufacturing valuation multiples in 2026 are a spectrum from 3x SDE to 12x+ EBITDA — not a single industry-wide number. The right answer depends on sub-vertical (machine shop versus contract manufacturer versus precision versus aerospace versus medical device), size band, capital intensity (4-7% maintenance capex creates a 15-30% gap between reported and cash EBITDA), customer concentration (25%/40%/50% thresholds), recurring contracted revenue percentage (60%+ supports premium), recession sensitivity by end-market, and the specific buyer pool that would actually look at your business. Triangulate from real data sources (GF Data, BVR DealStats, Pitchbook industrials, public 10-K disclosures from HEICO, APi Group, Atkore, Roper; trade association data from MAPI, AMT, NTMA, PMA), then validate against the 38 manufacturing-focused buyers in the LMM universe. The owners who realize the highest manufacturing multiples are the ones who start with sub-vertical-grounded multiple ranges, apply the structural adjusters honestly, and invest 18-24 months in the preparation moves that materially expand the multiple. And if you want to talk to someone who knows the 38 manufacturing-focused buyers personally instead of running an auction, we’re a buy-side partner — the buyers pay us, not you, no contract required. For a deeper look, see our guide on discover small business valuation multiples by sector. For a deeper look, see our guide on valuation multiples unlocking the key to business valuation.

Frequently Asked Questions

What is the average TEV/EBITDA multiple for manufacturing businesses in 2026?

The 2026 manufacturing TEV/EBITDA framework per GF Data DealStats, BVR DealStats, and Pitchbook industrials: sub-$10M EBITDA = 4-7x, $10-50M EBITDA = 6-9x, $50M+ EBITDA = 7-12x. The ‘average’ depends entirely on sub-vertical and size band. Aerospace AS9100/NADCAP shops trade 7-10x; medical device ISO 13485/FDA CMs trade 8-12x; general machine shops trade 3-5x SDE. The 4-9 turn spread between sub-verticals is real and explains why headline industry medians are misleading.

What multiple does a machine shop sell for?

General machine shops without specialty certifications trade at 3-5x SDE for sub-$1M SDE businesses, 4-6x EBITDA for $1-3M EBITDA businesses with real second-tier management. Multiple compression below 3x SDE happens when the owner is the lead programmer or estimator and the business cannot survive a 30-day owner absence. ISO 9001 certification is baseline and does not move the multiple meaningfully; AS9100 (aerospace) or ISO 13485 (medical) opens premium buyer pools at 7-10x and 8-12x respectively.

What is a typical EBITDA multiple for a contract manufacturer?

Contract manufacturers trade at 5-7x EBITDA for $2-10M EBITDA, 6-8x for $10-25M EBITDA. Premium for 60%+ recurring contracted revenue under multi-year LTAs, diversified customer base (top customer under 25%), ISO 9001+ certification, modern ERP discipline. Discount for project-based revenue without LTAs, customer concentration above 30%, capital-intensive sub-categories like injection molding (capex 6-9% of revenue compresses 0.5 turn). Active LMM buyers: Trive Capital, Mason Wells, Wynnchurch, Argosy Capital.

How does AS9100 certification affect aerospace manufacturer multiples?

AS9100D certification typically supports 7-10x EBITDA versus 4-7x for general machine shops — a 1-3 turn premium. NADCAP accreditation for special processes (NDT, heat treat, chemical processing) adds further premium. The reasoning: certification scarcity, OEM qualification cycles of 18-36 months locking incumbents in, 60%+ recurring contracted revenue from Tier-1 OEMs (Boeing, Airbus, Lockheed, Northrop, Spirit AeroSystems). Active aerospace LMM buyers: GenNx360, Audax Industrial, Arlington Capital, Greenbriar Equity, Cortec; strategic consolidators NASDAQ: HEICO (HEI), TransDigm.

What is a typical multiple for a medical device contract manufacturer?

Medical device CMs operating under FDA 21 CFR Part 820 with ISO 13485 certification trade at 8-12x EBITDA for $3-30M EBITDA businesses — the top of the manufacturing valuation range. Class III implantable device CMs trade 10-13x. Drivers: 2-5 year regulatory submission cycles creating customer lock-in, 70%+ recurring contracted revenue, demographic-aging tailwind. Buyers: medical-focused PE (Linden Capital Partners, Riverside Healthcare, GTCR Healthcare, Bain Healthcare) plus strategic acquirers (Integer Holdings [NYSE: ITGR], Phillips-Medisize, Tecomet, Cretex Medical).

Where do these manufacturing multiples come from?

Triangulated from five primary data sources: (1) GF Data DealStats (LMM transactions by NAICS and size), (2) BVR DealStats (M&A multiples database with sub-vertical breakdowns), (3) Pitchbook industrials reports (PE deal flow and aggregate trends), (4) public 10-K disclosures from serial industrial acquirers (NASDAQ: HEICO, NYSE: Atkore, NYSE: Roper, TransDigm, NYSE: APi Group), (5) trade association data (MAPI, AMT, NTMA, PMA, NAM). Government data from BLS, BEA, Federal Reserve, and Census Bureau provides macroeconomic context.

How does customer concentration affect manufacturing multiples?

Under 15% concentration: no discount. 15-25%: acknowledged but rarely repriced. 25-40%: 0.5-1.5 turn discount and earnout conversations. 40-50%: most LMM PE platforms require an earnout structure tied to customer retention. 50%+: deal compresses 1.5-3 turns and structure becomes heavily contingent. Mitigations: 3-5 year LTAs with volume commitments, sole-source designations, multi-program presence at the same OEM, AS9100/ISO 13485 certifications creating customer switching costs.

What is the recurring revenue premium in manufacturing?

30% recurring contracted revenue or below: 0.5-1 turn discount versus sub-vertical median. 30-50%: at-median pricing. 50-70%: +0.5 turn premium. 70%+: +1-1.5 turn premium and access to the premium buyer pool. Recurring = multi-year LTAs with volume commitments, sole-source production parts on OEM bills of materials, aftermarket service parts (the HEICO thesis), repeat-order industrial commodity production. NOT recurring = loyal customers without contracted volumes, project-based work, ad-hoc MRO.

How recession-sensitive are different manufacturing sub-verticals?

Aerospace commercial: low sensitivity with 18-36 month lag (production rates set in advance). Aerospace defense: counter-cyclical. Medical device (Class II/III): minimal sensitivity. General industrial CMs: moderate, 0.5-1 turn compression at troughs. Automotive Tier-2 passenger vehicle: high, 1-2 turn compression. Construction equipment CMs: high, 1-2 turn compression. Oil and gas equipment CMs: very high, 1.5-3 turn compression and binary in extreme cycles. Sophisticated buyers price on mid-cycle EBITDA, not peak.

Do public strategic consolidators pay more than LMM PE?

Yes, often 1-2 turns above the LMM PE multiple band when strategic fit is clear. Recent disclosed deals from NASDAQ: HEICO (HEI), NYSE: APi Group (APG), NYSE: Atkore (ATKR), NYSE: Roper Technologies (ROP), TransDigm, NYSE: Watsco (WSO), NYSE: Comfort Systems (FIX) range from 7-15x EBITDA. The premium drivers: lower cost of capital than PE, real synergy economics (revenue cross-sell, cost takeout, geographic coverage), and operational integration playbooks built over 50-100+ acquisitions.

How have manufacturing multiples shifted from 2019 to 2026?

Aerospace AS9100/NADCAP: expanded from 6-8x in 2020 to 7-10x in 2026, driven by Boeing 737 MAX recovery, Airbus rate increases, defense spending. Medical device ISO 13485/FDA: expanded from 7-10x in 2019 to 8-12x in 2026, driven by demographic-aging tailwind and regulatory moat depth. General CM: expanded modestly from 4.5-6x in 2019 to 5-7x in 2026 on reshoring narrative. Machine shop SDE: stable at 3-5x throughout the period (governed by SBA buyer economics). Plastics injection molding: expanded from 3.5-5x in 2019 to 4.5-6.5x in 2026 on automotive and aerospace pickup.

What is the difference between TEV and equity proceeds for manufacturing deals?

TEV (total enterprise value) is the headline price the buyer pays for the operating business cash-free, debt-free, with a working capital target. Equity proceeds = TEV − debt at close + excess cash ± working capital adjustment − transaction costs. The gap is typically 15-30% of TEV. Working capital alone (typically 20-30% of revenue for manufacturing) is the single biggest variable: a $14M revenue precision shop has a $4M working capital target, and unfavorable peg construction can give back $300K-$1M+ at close.

How is CT Acquisitions different from a sell-side broker or M&A advisor?

We’re a buy-side partner, not a sell-side broker. Sell-side brokers represent you and charge you 8-12% of the deal (often $300K-$1M+) plus monthly retainers, run a 9-12 month auction process, and require 12-month exclusivity. We work directly with 76+ buyers — including 38 firms with explicit manufacturing mandates: Audax Industrial, Industrial Growth Partners, GenNx360, Trive, Mason Wells, Wynnchurch, Sterling Group, Argosy, Cortec, GTCR Industrials, family offices, and strategic consolidators (HEICO, APi Group, Atkore, Roper, Comfort Systems, Watsco) — who pay us when a deal closes. You pay nothing. No retainer, no exclusivity, no contract until a buyer is at the closing table. We move faster (60-180 days from intro to close in many cases) because we already know which of the 38 manufacturing-focused buyers in the network would actually look at your business rather than running an auction to find one.

Sources & References

All claims and figures in this analysis are sourced from the publicly available references below.

1. https://www.nam.org/
2. https://www.amtonline.org/
3. https://www.ntma.org/
4. https://www.bls.gov/iag/tgs/iag31-33.htm
5. https://www.bea.gov/data/gdp/gdp-industry
6. https://investors.heico.com/financials/sec-filings
7. https://investors.atkore.com/financial-information/sec-filings
8. https://investors.apigroupinc.com/financial-information/sec-filings